天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (3): 333-336.doi: 10.11958/20211678

• 综述 • 上一篇    

环状RNA对房颤患者的影响及其作用机制研究

卢洁，张芯，王涛，杨宁   

  1. 1中国人民武装警察部队特色医学中心心血管内科（邮编300162）；2中国人民武装警察部队特色医学中心，心血管重塑与靶器官损伤重点实验室；3泰达国际心血管病医院
  • 出版日期:2022-03-15 发布日期:2022-03-22
  • 基金资助:
    国家重点研发计划（2017YFC307602）；天津市科技重大专项资助课题（15ZXJZSY00010）；天津市科技计划项目（16ZXMJSY00130）

Effects of circRNAs on atrial fibrillation and its mechanism

LU Jie, ZHANG Xin, WANG Tao, YANG Ning   

  1. 1 Department of Cardiology, Characteristic Medical Center of the Chinese People’s Armed Police Force, Tianjin 300162, China; 2 Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury, Characteristic Medical Center of the Chinese People’s Armed Police Force; 3 Tianjin Economic-Technological Development Area (TEDA) International Cardiovascular Hospital
  • Published:2022-03-15 Online:2022-03-22

PDF (PC)

3306

摘要： 心房颤动（房颤）是心内科常见的心律失常，主要原因是心脏传导系统异常，严重者可诱发心力衰竭、心源性休克、卒中及血栓栓塞性疾病而危及生命。房颤的早期诊断和预测一直是困扰临床工作者的重要难题，如何尽早甄别和预测房颤为临床重要任务。近年来，随着分子生物学技术的不断发展，越来越多的研究证实环状RNA能够参与房颤的发生并促进疾病的进展。汇总环状RNA对房颤发病过程的影响及其机制，有望为房颤的预防及分子靶向治疗提供新的见解，为患者争取更大的临床获益。

关键词: 心房颤动, 诊断, 分子靶向治疗, 生物标记, 环状RNA

Abstract: Atrial fibrillation (AF) is a common arrhythmia in department of cardiology, which is caused by abnormal cardiac conduction system. In severe cases, AF can induce heart failure, cardiogenic shock, stroke and thromboembolic disease, which is life-threatening. The early diagnosis and prediction of AF have always been an important problem for clinical workers. How to identify and predict AF as early as possible is the primary clinical task. In recent years, with the continuous development of molecular biology techniques, more and more studies have confirmed that circRNAs can participate in the occurrence of AF and promote the progression of the disease. To summarize the influence and mechanism of circRNAs in the pathogenesis of AF, we hope to provide new insights for the prevention and molecular targeted therapy of AF and strive for greater clinical benefits for patients.

Key words: atrial fibrillation, diagnosis, molecular targeted therapy, biomarkers, circular RNA